Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer
In the Netherlands a nationwide guideline was introduced in 2016, which recommended routine Lynch syndrome screening (LSS) for all women with endometrial cancer (EC)
Gespeichert in:
| Veröffentlicht in: | Gynecologic oncology 2021-03, Vol.160 (3), p.771-776 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 776 |
|---|---|
| container_issue | 3 |
| container_start_page | 771 |
| container_title | Gynecologic oncology |
| container_volume | 160 |
| creator | Tjalsma, A.S. Wagner, A. Dinjens, W.N.M. Ewing-Graham, P.C. Alcalá, L.S.M. de Groot, M.E.R. Hamoen, K.E. van Hof, A.C. Hofhuis, W. Hofman, L.N. Hoogduin, K.J. Kaijser, J. Makkus, A.C.F. Mol, S.J.J. Plaisier, G.M. Schelfhout, K. Smedts, H.P.M. Smit, R.A. Timmers, P.J. Vencken, P.M.L.H. Visschers, B. van der Wurff, A.A.M. van Doorn, H.C. |
| description | In the Netherlands a nationwide guideline was introduced in 2016, which recommended routine Lynch syndrome screening (LSS) for all women with endometrial cancer (EC) |
| doi_str_mv | 10.1016/j.ygyno.2020.12.028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2476562934</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825820342426</els_id><sourcerecordid>2476562934</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-7c919bf36519efa7d4880f5eeb3569d907a201e2b94bdd21a74918f0b5a161803</originalsourceid><addsrcrecordid>eNp9kD9vGzEMxYWiRe2k_QQBAo1dzqF0fzVkKNy0CWCgSzILOolnyzhLjqRzcN--Spx27ESCfI8P_BFyxWDFgDU3-9W8nZ1fceB5wlfAuw9kyUDURdPV4iNZAggoOl53C3IR4x4ASmD8M1mUZcVEA2JJtncnNU4qWe-oH6ii7q1_sQbpjynpHd1OuR-tQ5o8NZhQJ7qZXd7E2ZngD0ito8dsQ5cifbFpR9GZPE_BqpFq5TSGL-TToMaIX9_rJXn6efe4vi82v389rL9vCl1BlYpWCyb6oWxqJnBQram6DoYasS_rRhgBreLAkPei6o3hTLWVYN0Afa1YwzooL8m3891j8M8TxiQPNmocR-XQT1Hyqm3qhouyytLyLNXBxxhwkMdgDyrMkoF8JSz38o2wfCUsGZeZcHZdvwdM_QHNP89fpFlwexZgfvNkMcioMxqNxobMThpv_xvwBx2bjsk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476562934</pqid></control><display><type>article</type><title>Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer</title><source>Elsevier ScienceDirect Journals</source><creator>Tjalsma, A.S. ; Wagner, A. ; Dinjens, W.N.M. ; Ewing-Graham, P.C. ; Alcalá, L.S.M. ; de Groot, M.E.R. ; Hamoen, K.E. ; van Hof, A.C. ; Hofhuis, W. ; Hofman, L.N. ; Hoogduin, K.J. ; Kaijser, J. ; Makkus, A.C.F. ; Mol, S.J.J. ; Plaisier, G.M. ; Schelfhout, K. ; Smedts, H.P.M. ; Smit, R.A. ; Timmers, P.J. ; Vencken, P.M.L.H. ; Visschers, B. ; van der Wurff, A.A.M. ; van Doorn, H.C.</creator><creatorcontrib>Tjalsma, A.S. ; Wagner, A. ; Dinjens, W.N.M. ; Ewing-Graham, P.C. ; Alcalá, L.S.M. ; de Groot, M.E.R. ; Hamoen, K.E. ; van Hof, A.C. ; Hofhuis, W. ; Hofman, L.N. ; Hoogduin, K.J. ; Kaijser, J. ; Makkus, A.C.F. ; Mol, S.J.J. ; Plaisier, G.M. ; Schelfhout, K. ; Smedts, H.P.M. ; Smit, R.A. ; Timmers, P.J. ; Vencken, P.M.L.H. ; Visschers, B. ; van der Wurff, A.A.M. ; van Doorn, H.C.</creatorcontrib><description>In the Netherlands a nationwide guideline was introduced in 2016, which recommended routine Lynch syndrome screening (LSS) for all women with endometrial cancer (EC) <70 years of age. LSS consists of immunohistochemical (IHC) staining for loss of mismatch repair (MMR) protein expression, supplemented with MLH1 methylation analysis if indicated. Test results are evaluated by the treating gynaecologist, who refers eligible patients to a clinical geneticist. We evaluated the implementation of this guideline.
From the nation-wide pathology database we selected all women diagnosed with EC < 70 years of age, treated from 1.6.2016–1.6.2017 in 14 hospitals. We collected data on the results of LSS and follow up of cases with suspected LS.
In 183 out of 204 tumours (90%) LSS was performed. In 41 cases (22%) MMR protein expression was lost, in 25 cases due to hypermethylation of the MLH1 promotor. One patient was known with a pathogenic MLH1 variant. The option of genetic counselling was discussed with 12 of the 15 remaining patients, of whom three declined. After counselling by the genetic counsellor nine patients underwent germline testing. In two no pathogenic germline variant was detected, two were diagnosed with a pathogenic PMS2 variant, and five with a pathogenic MSH6 variant, in concordance with the IHC profiles.
Coverage of LSS was high (90%), though referral for genetic counselling could be improved. Gynaecologists ought to be aware of the benefits and possible drawbacks of knowing mutational status, and require training in discussing this with their patients.
•Implementation of Lynch syndrome screening in endometrial cancer can be improved.•Gynaecologists ought to be aware of Lynch syndrome screening in endometrial cancer and might require additional training.•Quality assurance protocols should be implemented to ensure adherence to Lynch syndrome screening in endometrial cancer.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2020.12.028</identifier><identifier>PMID: 33419609</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><ispartof>Gynecologic oncology, 2021-03, Vol.160 (3), p.771-776</ispartof><rights>2020 The Authors</rights><rights>Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-7c919bf36519efa7d4880f5eeb3569d907a201e2b94bdd21a74918f0b5a161803</citedby><cites>FETCH-LOGICAL-c404t-7c919bf36519efa7d4880f5eeb3569d907a201e2b94bdd21a74918f0b5a161803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0090825820342426$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33419609$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tjalsma, A.S.</creatorcontrib><creatorcontrib>Wagner, A.</creatorcontrib><creatorcontrib>Dinjens, W.N.M.</creatorcontrib><creatorcontrib>Ewing-Graham, P.C.</creatorcontrib><creatorcontrib>Alcalá, L.S.M.</creatorcontrib><creatorcontrib>de Groot, M.E.R.</creatorcontrib><creatorcontrib>Hamoen, K.E.</creatorcontrib><creatorcontrib>van Hof, A.C.</creatorcontrib><creatorcontrib>Hofhuis, W.</creatorcontrib><creatorcontrib>Hofman, L.N.</creatorcontrib><creatorcontrib>Hoogduin, K.J.</creatorcontrib><creatorcontrib>Kaijser, J.</creatorcontrib><creatorcontrib>Makkus, A.C.F.</creatorcontrib><creatorcontrib>Mol, S.J.J.</creatorcontrib><creatorcontrib>Plaisier, G.M.</creatorcontrib><creatorcontrib>Schelfhout, K.</creatorcontrib><creatorcontrib>Smedts, H.P.M.</creatorcontrib><creatorcontrib>Smit, R.A.</creatorcontrib><creatorcontrib>Timmers, P.J.</creatorcontrib><creatorcontrib>Vencken, P.M.L.H.</creatorcontrib><creatorcontrib>Visschers, B.</creatorcontrib><creatorcontrib>van der Wurff, A.A.M.</creatorcontrib><creatorcontrib>van Doorn, H.C.</creatorcontrib><title>Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>In the Netherlands a nationwide guideline was introduced in 2016, which recommended routine Lynch syndrome screening (LSS) for all women with endometrial cancer (EC) <70 years of age. LSS consists of immunohistochemical (IHC) staining for loss of mismatch repair (MMR) protein expression, supplemented with MLH1 methylation analysis if indicated. Test results are evaluated by the treating gynaecologist, who refers eligible patients to a clinical geneticist. We evaluated the implementation of this guideline.
From the nation-wide pathology database we selected all women diagnosed with EC < 70 years of age, treated from 1.6.2016–1.6.2017 in 14 hospitals. We collected data on the results of LSS and follow up of cases with suspected LS.
In 183 out of 204 tumours (90%) LSS was performed. In 41 cases (22%) MMR protein expression was lost, in 25 cases due to hypermethylation of the MLH1 promotor. One patient was known with a pathogenic MLH1 variant. The option of genetic counselling was discussed with 12 of the 15 remaining patients, of whom three declined. After counselling by the genetic counsellor nine patients underwent germline testing. In two no pathogenic germline variant was detected, two were diagnosed with a pathogenic PMS2 variant, and five with a pathogenic MSH6 variant, in concordance with the IHC profiles.
Coverage of LSS was high (90%), though referral for genetic counselling could be improved. Gynaecologists ought to be aware of the benefits and possible drawbacks of knowing mutational status, and require training in discussing this with their patients.
•Implementation of Lynch syndrome screening in endometrial cancer can be improved.•Gynaecologists ought to be aware of Lynch syndrome screening in endometrial cancer and might require additional training.•Quality assurance protocols should be implemented to ensure adherence to Lynch syndrome screening in endometrial cancer.</description><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kD9vGzEMxYWiRe2k_QQBAo1dzqF0fzVkKNy0CWCgSzILOolnyzhLjqRzcN--Spx27ESCfI8P_BFyxWDFgDU3-9W8nZ1fceB5wlfAuw9kyUDURdPV4iNZAggoOl53C3IR4x4ASmD8M1mUZcVEA2JJtncnNU4qWe-oH6ii7q1_sQbpjynpHd1OuR-tQ5o8NZhQJ7qZXd7E2ZngD0ito8dsQ5cifbFpR9GZPE_BqpFq5TSGL-TToMaIX9_rJXn6efe4vi82v389rL9vCl1BlYpWCyb6oWxqJnBQram6DoYasS_rRhgBreLAkPei6o3hTLWVYN0Afa1YwzooL8m3891j8M8TxiQPNmocR-XQT1Hyqm3qhouyytLyLNXBxxhwkMdgDyrMkoF8JSz38o2wfCUsGZeZcHZdvwdM_QHNP89fpFlwexZgfvNkMcioMxqNxobMThpv_xvwBx2bjsk</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Tjalsma, A.S.</creator><creator>Wagner, A.</creator><creator>Dinjens, W.N.M.</creator><creator>Ewing-Graham, P.C.</creator><creator>Alcalá, L.S.M.</creator><creator>de Groot, M.E.R.</creator><creator>Hamoen, K.E.</creator><creator>van Hof, A.C.</creator><creator>Hofhuis, W.</creator><creator>Hofman, L.N.</creator><creator>Hoogduin, K.J.</creator><creator>Kaijser, J.</creator><creator>Makkus, A.C.F.</creator><creator>Mol, S.J.J.</creator><creator>Plaisier, G.M.</creator><creator>Schelfhout, K.</creator><creator>Smedts, H.P.M.</creator><creator>Smit, R.A.</creator><creator>Timmers, P.J.</creator><creator>Vencken, P.M.L.H.</creator><creator>Visschers, B.</creator><creator>van der Wurff, A.A.M.</creator><creator>van Doorn, H.C.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202103</creationdate><title>Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer</title><author>Tjalsma, A.S. ; Wagner, A. ; Dinjens, W.N.M. ; Ewing-Graham, P.C. ; Alcalá, L.S.M. ; de Groot, M.E.R. ; Hamoen, K.E. ; van Hof, A.C. ; Hofhuis, W. ; Hofman, L.N. ; Hoogduin, K.J. ; Kaijser, J. ; Makkus, A.C.F. ; Mol, S.J.J. ; Plaisier, G.M. ; Schelfhout, K. ; Smedts, H.P.M. ; Smit, R.A. ; Timmers, P.J. ; Vencken, P.M.L.H. ; Visschers, B. ; van der Wurff, A.A.M. ; van Doorn, H.C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-7c919bf36519efa7d4880f5eeb3569d907a201e2b94bdd21a74918f0b5a161803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tjalsma, A.S.</creatorcontrib><creatorcontrib>Wagner, A.</creatorcontrib><creatorcontrib>Dinjens, W.N.M.</creatorcontrib><creatorcontrib>Ewing-Graham, P.C.</creatorcontrib><creatorcontrib>Alcalá, L.S.M.</creatorcontrib><creatorcontrib>de Groot, M.E.R.</creatorcontrib><creatorcontrib>Hamoen, K.E.</creatorcontrib><creatorcontrib>van Hof, A.C.</creatorcontrib><creatorcontrib>Hofhuis, W.</creatorcontrib><creatorcontrib>Hofman, L.N.</creatorcontrib><creatorcontrib>Hoogduin, K.J.</creatorcontrib><creatorcontrib>Kaijser, J.</creatorcontrib><creatorcontrib>Makkus, A.C.F.</creatorcontrib><creatorcontrib>Mol, S.J.J.</creatorcontrib><creatorcontrib>Plaisier, G.M.</creatorcontrib><creatorcontrib>Schelfhout, K.</creatorcontrib><creatorcontrib>Smedts, H.P.M.</creatorcontrib><creatorcontrib>Smit, R.A.</creatorcontrib><creatorcontrib>Timmers, P.J.</creatorcontrib><creatorcontrib>Vencken, P.M.L.H.</creatorcontrib><creatorcontrib>Visschers, B.</creatorcontrib><creatorcontrib>van der Wurff, A.A.M.</creatorcontrib><creatorcontrib>van Doorn, H.C.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tjalsma, A.S.</au><au>Wagner, A.</au><au>Dinjens, W.N.M.</au><au>Ewing-Graham, P.C.</au><au>Alcalá, L.S.M.</au><au>de Groot, M.E.R.</au><au>Hamoen, K.E.</au><au>van Hof, A.C.</au><au>Hofhuis, W.</au><au>Hofman, L.N.</au><au>Hoogduin, K.J.</au><au>Kaijser, J.</au><au>Makkus, A.C.F.</au><au>Mol, S.J.J.</au><au>Plaisier, G.M.</au><au>Schelfhout, K.</au><au>Smedts, H.P.M.</au><au>Smit, R.A.</au><au>Timmers, P.J.</au><au>Vencken, P.M.L.H.</au><au>Visschers, B.</au><au>van der Wurff, A.A.M.</au><au>van Doorn, H.C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2021-03</date><risdate>2021</risdate><volume>160</volume><issue>3</issue><spage>771</spage><epage>776</epage><pages>771-776</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>In the Netherlands a nationwide guideline was introduced in 2016, which recommended routine Lynch syndrome screening (LSS) for all women with endometrial cancer (EC) <70 years of age. LSS consists of immunohistochemical (IHC) staining for loss of mismatch repair (MMR) protein expression, supplemented with MLH1 methylation analysis if indicated. Test results are evaluated by the treating gynaecologist, who refers eligible patients to a clinical geneticist. We evaluated the implementation of this guideline.
From the nation-wide pathology database we selected all women diagnosed with EC < 70 years of age, treated from 1.6.2016–1.6.2017 in 14 hospitals. We collected data on the results of LSS and follow up of cases with suspected LS.
In 183 out of 204 tumours (90%) LSS was performed. In 41 cases (22%) MMR protein expression was lost, in 25 cases due to hypermethylation of the MLH1 promotor. One patient was known with a pathogenic MLH1 variant. The option of genetic counselling was discussed with 12 of the 15 remaining patients, of whom three declined. After counselling by the genetic counsellor nine patients underwent germline testing. In two no pathogenic germline variant was detected, two were diagnosed with a pathogenic PMS2 variant, and five with a pathogenic MSH6 variant, in concordance with the IHC profiles.
Coverage of LSS was high (90%), though referral for genetic counselling could be improved. Gynaecologists ought to be aware of the benefits and possible drawbacks of knowing mutational status, and require training in discussing this with their patients.
•Implementation of Lynch syndrome screening in endometrial cancer can be improved.•Gynaecologists ought to be aware of Lynch syndrome screening in endometrial cancer and might require additional training.•Quality assurance protocols should be implemented to ensure adherence to Lynch syndrome screening in endometrial cancer.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33419609</pmid><doi>10.1016/j.ygyno.2020.12.028</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-8258 |
| ispartof | Gynecologic oncology, 2021-03, Vol.160 (3), p.771-776 |
| issn | 0090-8258 1095-6859 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2476562934 |
| source | Elsevier ScienceDirect Journals |
| title | Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T13%3A23%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20a%20nationwide%20Dutch%20guideline%20to%20detect%20Lynch%20syndrome%20in%20patients%20with%20endometrial%20cancer&rft.jtitle=Gynecologic%20oncology&rft.au=Tjalsma,%20A.S.&rft.date=2021-03&rft.volume=160&rft.issue=3&rft.spage=771&rft.epage=776&rft.pages=771-776&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2020.12.028&rft_dat=%3Cproquest_cross%3E2476562934%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476562934&rft_id=info:pmid/33419609&rft_els_id=S0090825820342426&rfr_iscdi=true |